Compare SUVEN LIFE with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFESCIENCES vs STRIDES PHARMA SCIENCE - Comparison Results

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFESCIENCES STRIDES PHARMA SCIENCE SUVEN LIFESCIENCES/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 3.9 16.3 24.2% View Chart
P/BV x 0.6 1.0 58.1% View Chart
Dividend Yield % 4.0 0.5 813.2%  

Financials

 SUVEN LIFESCIENCES   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    SUVEN LIFESCIENCES
Mar-19
STRIDES PHARMA SCIENCE
Mar-18
SUVEN LIFESCIENCES/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs3381,147 29.4%   
Low Rs169642 26.4%   
Sales per share (Unadj.) Rs52.1317.2 16.4%  
Earnings per share (Unadj.) Rs6.87.8 87.1%  
Cash flow per share (Unadj.) Rs8.625.1 34.2%  
Dividends per share (Unadj.) Rs1.502.00 75.0%  
Dividend yield (eoy) %0.60.2 264.6%  
Book value per share (Unadj.) Rs65.3274.3 23.8%  
Shares outstanding (eoy) m127.2889.50 142.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.92.8 172.5%   
Avg P/E ratio x37.1114.0 32.6%  
P/CF ratio (eoy) x29.635.7 82.9%  
Price / Book Value ratio x3.93.3 119.1%  
Dividend payout %22.025.5 86.1%   
Avg Mkt Cap Rs m32,27280,058 40.3%   
No. of employees `0001.12.5 43.2%   
Total wages/salary Rs m6614,341 15.2%   
Avg. sales/employee Rs Th6,132.211,325.8 54.1%   
Avg. wages/employee Rs Th611.11,731.4 35.3%   
Avg. net profit/employee Rs Th803.5280.1 286.9%   
INCOME DATA
Net Sales Rs m6,63528,394 23.4%  
Other income Rs m242941 25.8%   
Total revenues Rs m6,87729,334 23.4%   
Gross profit Rs m1,6043,965 40.5%  
Depreciation Rs m2211,540 14.4%   
Interest Rs m381,962 1.9%   
Profit before tax Rs m1,5871,403 113.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m71897 737.9%   
Profit after tax Rs m869702 123.8%  
Gross profit margin %24.214.0 173.1%  
Effective tax rate %45.26.9 652.3%   
Net profit margin %13.12.5 529.9%  
BALANCE SHEET DATA
Current assets Rs m6,23224,836 25.1%   
Current liabilities Rs m1,49018,993 7.8%   
Net working cap to sales %71.520.6 347.3%  
Current ratio x4.21.3 319.8%  
Inventory Days Days8671 121.8%  
Debtors Days Days83113 72.8%  
Net fixed assets Rs m4,04334,289 11.8%   
Share capital Rs m127895 14.2%   
"Free" reserves Rs m8,18323,651 34.6%   
Net worth Rs m8,31024,546 33.9%   
Long term debt Rs m1815,513 0.1%   
Total assets Rs m10,38965,437 15.9%  
Interest coverage x43.11.7 2,513.4%   
Debt to equity ratio x00.6 0.3%  
Sales to assets ratio x0.60.4 147.2%   
Return on assets %8.74.1 214.4%  
Return on equity %10.52.9 365.8%  
Return on capital %19.56.9 283.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62215,697 35.8%   
Fx outflow Rs m1,799735 244.7%   
Net fx Rs m3,82214,962 25.5%   
CASH FLOW
From Operations Rs m3561,871 19.0%  
From Investments Rs m-2795,826 -4.8%  
From Financial Activity Rs m-225-10,157 2.2%  
Net Cashflow Rs m-148-2,615 5.7%  

Share Holding

Indian Promoters % 63.4 27.7 228.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 37.8 -  
FIIs % 0.0 8.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 25.9 140.9%  
Shareholders   37,287 56,241 66.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFESCIENCES With:   DIVIS LABORATORIES  WOCKHARDT  AUROBINDO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  

Compare SUVEN LIFESCIENCES With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Tanks 661 Points; Banking and Finance Stocks Witness Huge Selling(Closing)

Indian share markets fell sharply today, led by weak Asian equities as worries of new lockdowns to stem surging coronavirus cases kept investors cautious worldwide.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)

Jul 22, 2019 | Updated on Jul 22, 2019

Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.

SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

How to Find the Best Stocks for Day Trading - 1(Fast Profits Daily)

Jul 2, 2020

In the first of two videos, I'll show you how to identify the best stocks for intraday trading.

Two Agri Stocks Are Likely to Outperform Even in this Market(Profit Hunter)

Jul 2, 2020

Why we have recommended two agriculture stocks for our Hidden Treasure subscribers. Read on...

These 3 Recent Events Will Impact the Price of Gold(Fast Profits Daily)

Jul 1, 2020

Recent developments in the bullion market may put some short term pressure on gold prices.

Smallcaps Are in a Sweet Spot Again: Are You Buying?(Profit Hunter)

Jul 3, 2020

This is why I believe smallcaps are the place to be in the near future.

More

India's #1 Trader
Reveals His Secrets

The Secret to Increasing Your Trading Profits Today
Get this Special Report, The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFESCIENCES SHARE PRICE


Jul 14, 2020 (Close)

TRACK SUVEN LIFESCIENCES

  • Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFESCIENCES

SUVEN LIFESCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFESCIENCES WITH

MARKET STATS